Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

  • STATUS
    Recruiting
  • End date
    May 1, 2024
  • participants needed
    25
  • sponsor
    Azienda Ospedaliero-Universitaria Careggi
Updated on 23 January 2021

Summary

The aim of this study is to prospectively evaluate, in patients affected by early breast cancer, safety and feasibility of single fraction radiotherapy with Cyberknife R in preoperative setting, and to identify factors predictive for outcome based on biologic and clinical parameters.

Description

Monocentric, open-label, single-arm phase II study evaluating safety and efficacy of neoadjuvant radiotherapy in early breast cancer patients. Patients eligible are women aged 50 or more years old, affected by histologically proven invasive breast cancer, with positive hormonal receptors, grading 1 or 2, HER-2 negative, without lymphovascular invasion, and tumour size up to 2 cm (measured on mammography, ultrasound or magnetic resonance), negative clinical nodal status, eligible for BCS.

Details
Condition Early Breast Cancer
Treatment Neoadjuvant radiotherapy
Clinical Study IdentifierNCT03520894
SponsorAzienda Ospedaliero-Universitaria Careggi
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed informed consent
Women 50 years old
Histological diagnosis of invasive breast cancer
ER positive ( 10% of tumoral cells present ER) and/or PR positive ( 10% of tumoral cells present PR)
Grading 1 or 2
Her2 negative (IHC 0-1+; in patients with IHC 2+, absence of amplification at FISH
No lymphovascular invasion evidence at biopsy
Early breast cancer (T1 N0 M0) clinically and radiologically defined (ultrasound study/ magnetic resonance)
Patients eligible for BCS

Exclusion Criteria

Extension of breast disease within 5 mm from the skin surface 2. Tumor size
> 2 cm 3. Patients affected by collagenopathies 4. Patients with BRCA1/2
mutations 5. Previous irradiation to homolateral breast 6. Previous
irradiation to homolateral thoracic wall 7. DCIS and/or Paget's disease 8
Psychiatric disorders preventing informed consent signature
\-
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note